262 related articles for article (PubMed ID: 18986281)
21. Fluoroquinolones in the management of community-acquired pneumonia.
Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
[TBL] [Abstract][Full Text] [Related]
22. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
23. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia.
Strålin K
Int J Antimicrob Agents; 2008 Jan; 31(1):3-11. PubMed ID: 17920819
[TBL] [Abstract][Full Text] [Related]
25. How long should we treat community-acquired pneumonia?
Scalera NM; File TM
Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
[TBL] [Abstract][Full Text] [Related]
26. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
[TBL] [Abstract][Full Text] [Related]
27. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
28. Novel targets in the management of pneumonia.
Díaz LA; Mortensen EM; Anzueto A; Restrepo MI
Ther Adv Respir Dis; 2008 Dec; 2(6):387-400. PubMed ID: 19124384
[TBL] [Abstract][Full Text] [Related]
29. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
30. [Reducing the duration of antibiotic therapy in acute community-acquired pneumonia].
Groupe Entretiens du Club de réflexion sur l'infection respiratoire
Rev Pneumol Clin; 2008 Feb; 64(1):3-7. PubMed ID: 18603172
[TBL] [Abstract][Full Text] [Related]
31. One drug or two? Step-down therapy after i.v. antibiotics for community-acquired pneumonia.
Harrington Z; Barnes DJ
Intern Med J; 2007 Nov; 37(11):767-71. PubMed ID: 17908087
[TBL] [Abstract][Full Text] [Related]
32. Corticosteroid treatment of severe community-acquired pneumonia.
Gorman SK; Slavik RS; Marin J
Ann Pharmacother; 2007 Jul; 41(7):1233-7. PubMed ID: 17519300
[TBL] [Abstract][Full Text] [Related]
33. New trends in the prevention and management of community-acquired pneumonia.
Postma DF; van Werkhoven CH; Huijts SM; Bolkenbaas M; Oosterheert JJ; Bonten MJ
Neth J Med; 2012 Oct; 70(8):337-48. PubMed ID: 23065981
[TBL] [Abstract][Full Text] [Related]
34. Why should we measure bacterial load when treating community-acquired pneumonia?
Waterer G; Rello J
Curr Opin Infect Dis; 2011 Apr; 24(2):137-41. PubMed ID: 21301334
[TBL] [Abstract][Full Text] [Related]
35. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
36. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
Hak E; Grobbee DE; Sanders EA; Verheij TJ; Bolkenbaas M; Huijts SM; Gruber WC; Tansey S; McDonough A; Thoma B; Patterson S; van Alphen AJ; Bonten MJ
Neth J Med; 2008 Oct; 66(9):378-83. PubMed ID: 18990781
[TBL] [Abstract][Full Text] [Related]
39. Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history.
Gwaltney JM; Wiesinger BA; Patrie JT
Clin Infect Dis; 2004 Jan; 38(2):227-33. PubMed ID: 14699455
[TBL] [Abstract][Full Text] [Related]
40. Community-acquired pneumonia: the U.S. perspective.
Niederman MS
Semin Respir Crit Care Med; 2009 Apr; 30(2):179-88. PubMed ID: 19296418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
